Daily non-political popular news in brief.

Cancer cell line developed that is resistant to new cancer therapy

12-11-2007 · EurekAlert!

A cancer cell line that is resistant to one of the newest classes of cancer treatments has been developed by researchers who already are using it to determine what else to give patients when this happens.

Keywords: cancer, cell, line, developed, resistant, therapy

« Previous | Next »

Similar news on "Cancer cell line developed that is resistant to new cancer therapy":

Pre-treatment blood test could guide lung cancer therapy
06-05-2007 · EurekAlert!
A multi-center team, led by Vanderbilt-Ingram Cancer Center investigators, has developed a new pre-treatment blood test that predicts which non-small-cell lung cancer patients will live longer when they are treated with certain targeted cancer therapies (Iressa, Tarceva). The mass spectrometry-based test, described in the June 6 Journal of the National Cancer Institute, may allow physicians to select the most beneficial therapy for each lung cancer patient, a step forward in the era of personalized medicine.
Similar news · Read more »
Sutent achieves first line EAU approval for kidney cancer
03-22-2007 · EurekAlert!
Sutent (sunitinib malate) has received a European Association of Urology recommendation, as first-line therapy in patients with metastatic renal cell carcinoma of good and intermediate risk, just two months after gaining EU marketing authorization for first line use in all patients with advanced and/or metastatic renal cell carcinoma.
Similar news · Read more »
Jefferson scientists find protein potential drug target for treatment-resistant prostate cancer
12-31-2007 · EurekAlert!
Scientists at Jefferson's Kimmel Cancer Center in Philadelphia have found that a signaling protein that is key to prostate cancer cell growth is turned on in nearly all recurrent prostate cancers that are resistant to hormone therapy. If the findings hold up, the protein, called Stat5, may be a specific drug target against an extremely difficult-to-treat cancer.
Similar news · Read more »
Clinical data suggest potential versatility of ALIMTA-based regimens in lung cancer
06-02-2007 · EurekAlert!
ALIMTA (pemetrexed for injection) showed additional utility in the treatment of the most diagnosed type of cancer, according to data presented today at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO). Results from a Phase III study suggest that a first-line ALIMTA-based regimen may deliver less toxicity than a commonly used therapy in advanced non-small cell lung cancer (NSCLC). ALIMTA is manufactured and marketed by Eli Lilly and Company.
Similar news · Read more »
ESF EURYI award winner aims to stop cancer cells reading their own DNA
08-09-2007 · EurekAlert!
A promising new line in anticancer therapy by blocking the molecular motors involved in copying genetic information during cell division is being pursued by young Dutch researcher Dr. Nynke Dekker in one of this year's EURYI award winning projects sponsored by the European Science Foundation and the European Heads of Research Councils.
Similar news · Read more »
How can we know early who will benefit from tumor target therapy?
11-21-2007 · EurekAlert!
A 55-year-old male patient had developed advanced hepatic metastasis and peritoneal carcinomatosis after remnant gastric cancer resection three months earlier. The patient only received target therapy, including Cetuximab plus recombinant human endostatin treatment. Anti-tumor activity assessed by 18F-fluorodeoxyglucose positron emission tomography/computer tomography scan at baseline, then every four weeks afterward showed that 18FDG-PET/CT could make an early prediction of the response to cetuximab plus Endostar in such clinical situations.
Similar news · Read more »
Novel vaccine concept developed by scientists at the Wistar Institute
01-31-2008 · EurekAlert!
A new vaccine design strategy developed by scientists at the Wistar Institute could help to develop vaccines against diseases like AIDS and cervical cancer. The secret is using a herpes simplex protein called glycoprotein D to block a receptor molecule on antigen-presenting cells. Wistar scientists showed that vaccine vectors made by fusing glycoprotein D with genes from HIV and HPV antigens increase the immune system's response to those antigens in cell cultures and mice.
Similar news · Read more »
Antiprotons 4 times more effective than protons for cell irradiation
10-31-2006 · EurekAlert!
A pioneering experiment at CERN with potential future application in cancer therapy has produced its first results. Started in 2003, ACE (Antiproton Cell Experiment) is the first investigation of the biological effects of antiprotons.
Similar news · Read more »
Scientists map key landmarks in human genome
01-16-2007 · EurekAlert!
Dana-Farber Cancer Institute researchers have developed a powerful method for charting the positions of key gene-regulating molecules called nucleosomes throughout the human genome. The mapping tool could help uncover important clues for understanding and diagnosing cancer and other diseases, the scientists say. Moreover, it may shed light on the role of nucleosomes in the process of "reprogramming" an adult cell to its original embryonic state, which is a critical operation in cloning.
Similar news · Read more »
Scientists follow familiar TRAIL to new cancer therapy
07-09-2007 · EurekAlert!
A new study identifies a combination therapy that may sensitize human cancer cells to a promising treatment currently being used in clinical trials. The research, published in the July issue of the journal Cancer Cell, published by Cell Press, provides a pharmacological method for enhancing the potency and effectiveness of a tumor necrosis factor death receptor ligand against a variety of human cancers.
Similar news · Read more »